Targeted Genetics presents advances in systemic gene delivery ...( iting tumor growth than was 5FU a chem...)

iting tumor growth than was 5FU, a chemotherapy agent frequently used to treat head and neck tumors in humans. We are very encouraged by these results and are moving forward aggressively in the development of the LPD delivery system. Systemic delivery of E1A may provide a new gene therapy approach to treating patients with metastatic disease or other cancers that are not amenable to treatment by direct injection."

Previous studies have shown that tgLPD-E1A also inhibits tumor growth in a mouse xenograft model of breast cancer tumors. Significantly, the combination of tgLPD-E1A and paclitaxel inhibited tumor growth three-fold more efficiently than did paclitaxel alone. These data and studies evaluating tgDCC-E1A in combination with chemotherapy indicate that E1A sensitizes tumor cells to chemotherapeutic agents . Targeted Genetics is evaluating tgDCC-E1A (the company's local gene delivery formulation) in Phase II trials for head and neck cancer and in Phase I trials in combination with chemotherapy for ovarian cancer. Data from the Phase II trial are to be presented at the 36th American Society of Clinical Oncology Annual Meeting in May of this year. Patient enrollment in the Phase I trial is expected to be completed by the end of the year. The Company intends to begin human clinical trials of tgLPD-E1A in 2001.

"These data suggest that we are moving closer to attaining the holy grail of gene therapy a systemic delivery system," said Dr. Barrie J. Carter, Executive Vice President and Director of Research and Development at Targeted Genetics. "Our ability to deliver genes systemically will expand the number of diseases that may be treatable with gene therapy approaches. We are very excited about the progress we are making in developing a variety of synthetic gene delivery systems, including formulations for systemic and local delivery."

Targeted Genetics is developing a variety of synthetic gene delivery systems, both
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x229
Noonan/Russo Communications
2-Apr-2000

Page: 1 2 3 4
Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. Targeted therapy for lung cancer patients shows promise in extending lives
3. Targeted immunotherapy eradicates cancer in mice
4. Targeted radiation to liver tumors spares tissue, improves quality of life
5. Targeted Genetics presents data on arthritis gene therapy
6. Targeted genetics presents promising data from cystic fibrosis clinical trial
7. Targeted Genetics presents clinical data on E1A cancer gene therapy
8. Targeted Genetics presents advances in synthetic gene delivery technologies
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin